A news brief in the Dec. 4, 2003, issue of BioWorld Today should have said that data reported at the San Antonio Breast Cancer Symposium showed that researchers found an increased level of insulin-like growth factor receptor in breast carcinoma cells resistant to Herceptin, while treatment with Insmed Inc.'s rhIGFBP-3 caused dose-dependent inhibition of Herceptin-resistant breast carcinoma growth. The product combined with Herceptin caused a dose-dependent increase in sensitivity of breast carcinoma cells to Herceptin.

Editor's note: The changes have been made in BioWorld Online.